Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Nov;55(11):403-7.
doi: 10.3345/kjp.2012.55.11.403. Epub 2012 Nov 23.

Understanding noninferiority trials

Seokyung Hahn  1
Affiliations

Understanding noninferiority trials

Seokyung Hahn. Korean J Pediatr. 2012 Nov.

Abstract

Noninferiority trials test whether a new experimental treatment is not unacceptably less efficacious than an active control treatment already in use. With continuous improvements in health technologies, standard care, and clinical outcomes, the incremental benefits of newly developed treatments may be only marginal over existing treatments. Sometimes assigning patients to a placebo is unethical. In such circumstances, there has been increasing emphasis on the use of noninferiority trial designs. Noninferiority trials are more complex to design, conduct, and interpret than typical superiority trials. This paper reviews the concept of noninferiority trials and discusses some important issues related to them.

Keywords: Clinical trials; Controlled clinical trials; Noninferiority trial; Randomized controlled clinical trials.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Testing superiority, equivalence/noninferiority. Δ: margin for equivalence/noninferiority.
Fig. 2
Fig. 2
Noninferiority margin. The positioning of the outcome result for each treatment is indicated. Δ: margin for equivalence/noninferiority.
Fig. 3
Fig. 3
Hypothetical scenario. Numbers represent the values of a positive outcome. The noninferiority margin is determined by halving the control effect, based on a historical placebo-controlled trial. The upper limit of the 95% confidence interval (CI) for the treatment difference by the new treatment compared to the control is less than the margin to conclude noninferiority, although there is an implication of incomparability. Δ: margin for equivalence/noninferiority.
See this image and copyright information in PMC

References

    1. Rosato R, Ciccone G, Bo S, Pagano GF, Merletti F, Gregori D. Evaluating cardiovascular mortality in type 2 diabetes patients: an analysis based on competing risks Markov chains and additive regression models. J Eval Clin Pract. 2007;13:422–428. - PubMed
    1. Stephan BC, Kurth T, Matthews FE, Brayne C, Dufouil C. Dementia risk prediction in the population: are screening models accurate? Nat Rev Neurol. 2010;6:318–326. - PubMed
    1. Temple R, Ellenberg SS. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med. 2000;133:455–463. - PubMed
    1. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med. 2000;133:464–470. - PubMed
    1. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141–145. - PubMed

LinkOut - more resources